Holz, MD, global head of clinical development at Biocon Biologics, discussed the approval of BMAb-1200, a biosimilar to reference ustekinumab for psoriasis, highlighting comparable efficacy and safety ...

Teva and Samsung Bioepis have launched Epysqli, a cost-saving Soliris biosimilar, offering a 30% discount and new hope for ...

Early market entry, manufacturing efficiency, and market share are critical to biosimilar development success, while ...

Lawmakers and expert witnesses emphasized the potential of biosimilars to lower health care costs by overcoming barriers like pharmacy benefit manager practices, limited awareness, and regulatory ...

Affirming that analytical characterization is often sufficient for biosimilar approval, minimizing unnecessary clinical ...

As the biosimilar industry celebrates a decade of growth, the market continues to evolve with expanded treatment options, ...

The ranibizumab biosimilar Ongavia exhibited significantly less improvement in visual acuity and retinal thickness compared ...

Number 5: Bevacizumab biosimilars Mvasi and Zirabev provided cost savings for metastatic colorectal cancer (mCRC) treatment without compromising effectiveness. Number 4: High adherence rates, ...

Number 5: Biosimilar natalizumab demonstrated comparable efficacy, safety, and immunogenicity to reference drug Tysabri in patients with relapsing-remitting multiple sclerosis (RRMS), supporting its ...